ClinicalTrials.gg
Active, not recruitingNCT05194995Updated Mar 16, 2026

JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

A Phase 1/2 interventional study of JAB-21822 and Cetuximab in Advanced Colorectal Cancer, Small Intestinal Cancer and Appendiceal Cancer, sponsored by Allist Pharmaceuticals, Inc.. Active, not recruiting at 17 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Allist Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of JAB-21822 in combination with cetuximab in patients with advanced colorectal cancer,advanced small intestine cancer and advanced appendiceal cancer with KRAS p.G12C mutation.

Read the detailed description

The primary objective of this study is to evaluate the safety and tolerability of JAB-21822 in combination with cetuximab to determine the MTD and RP2D during Dose Escalation phase; then to evaluate preliminary antitumor activity when JAB-21822 is administered in combination with cetuximab during Dose Expansion phase in patients with advanced colorectal cancer,advanced small intestine cancer and advanced appendiceal cancer with KRAS p.G12C mutation.

02

Conditions studied

  • Advanced Colorectal Cancer
  • Small Intestinal Cancer
  • Appendiceal Cancer

Browse trials for

03

In context

Appendiceal Neoplasms

86 studies on the registry are indexed under Appendiceal Neoplasms; 25 are open to participants now.

This study's enrollment of 48 is close to the median of 44 across 63 interventional studies indexed under Appendiceal Neoplasms.

Browse Appendiceal Neoplasms studies →

Lead sponsor

Allist Pharmaceuticals, Inc. is the lead sponsor of 25 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be able to provide an archived tumor sample
  • or cytologically confirmed advanced colorectal cancer, advanced small intestinal cancer and advanced appendiceal cancer with KRAS p.G12C mutation
  • Must have received at least 1 prior standard therapy
  • Must have at least 1 per v1.1
  • Must have adequate organ function
  • Must be able to swallow and retain orally administered medication

Exclusion criteria

Exclusion Criteria:

  • Has , except if treated and no evidence of radiographic progression or hemorrhage for at least 28 days
  • Active infection requiring systemic treatment within 14 days
  • Active , or
  • Any severe and/or uncontrolled medical conditions
  • \<50% assessed by ECHO
  • >470 msec
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Phase 1b Dose Escalation

    Dose escalation of JAB-21822 to determine maximum tolerated dose of JAB-21822 in combination with cetuximab.

    Drug: JAB-21822 · Drug: Cetuximab

  • Experimental
    Phase 2 Dose Expansion, Cohort 1

    Enrollment into the dose expansion cohort is for eligible participants with KRAS P.G12C mutant advanced colorectal cancer.

    Drug: JAB-21822 · Drug: Cetuximab

  • Experimental
    Phase 2 Dose Expansion, Cohort 2

    Enrollment into the dose expansion cohort is for eligible participants with KRAS P.G12C mutant advanced small intestinal cancer and advanced appendiceal cancer.

    Drug: JAB-21822 · Drug: Cetuximab

Interventions

  • JAB-21822 administered orally as a tablet.

  • Cetuximab administered as an intravenous (IV) infusion.

06

What researchers measure

Primary outcomes

  1. Dose Escalation phase: Number of participants with dose-limiting toxicities (DLTs)

    A DLT is defined as the clinically significant treatment related adverse event (TRAE) or abnormal laboratory values assessment during the first 21 days of (Cycle 1) and excludes events that are deemed clearly related to underlying disease, progression, or intercurrent illness.

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

  2. Dose Expansion phase: Overall response rate (ORR)

    ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) per RECIST v 1.1.

    Time frame: Up to 4 years - from baseline to RECIST confirmed Progressive Disease

Secondary outcomes

  1. Dose Escalation and Dose Expansion phase: Number of participants with adverse events

    Patients will be assessed for incidence and severity of adverse events (AEs) according to NCI-CTCAE criteria.

    Time frame: Up to 4 years

  2. Dose Escalation and Dose Expansion phase: Peak Plasma Concentration (Cmax)

    Cmax of JAB-21822 will be measured by using plasma PK samples.

    Time frame: Up to 4 years

  3. Dose Escalation and Dose Expansion phase: Area under the plasma concentration versus time curve (AUC)

    AUC of JAB-21822 will be measured by using plasma PK samples.

    Time frame: Up to 4 years

  4. Dose Expansion phase: Duration of response ( DOR )

    DOR is defined as the time from the participant's initial objective response (CR or PR) to disease progression per CTCAE v1.1 or death due to any cause, whichever occurs first.

    Time frame: Up to 4 years

  5. Dose Escalation phase: Overall response rate (ORR)

    The percentage of participants with complete response (CR) or partial response (PR) on RECIST v 1.1.

    Time frame: Up to 4 years

  6. Dose Expansion phase: Disease Control Rate ( DCR )

    DCR is defined as percentage of participants with complete response (CR), partial response (PR), or stable disease(SD) per CTCAE v1.1.

    Time frame: Up to 4 years

  7. Dose Expansion phase: Progression-free survival (PFS)

    PFS is defined as the interval of time between the date of first treatment to the earliest date of disease progression per CTCAE v1.1 or death which occurs first.

    Time frame: Up to 4 years

07

Study locations

17 sites
  • Research site31
    Beijing, Beijing Municipality 100021, China
  • Research site01
    Beijing, Beijing Municipality 100101, China
  • Research site02
    Beijing, Beijing Municipality 100101, China
  • Research site12
    Beijing, Beijing Municipality 100101, China
  • Research site13
    Nanning, Guangxi 530021, China
  • Research site06
    Harbin, Heilongjiang 150000, China
  • Research site05
    Zhengzhou, Henan 450000, China
  • Research site07
    Zhengzhou, Henan 450000, China
  • Research site18
    Wuhan, Hubei 430079, China
  • Research site11
    Changsha, Hunan 410000, China
  • Research site29
    Changsha, Hunan 410000, China
  • Research site09
    Nanjing, Jiangsu 210000, China
  • Research site08
    Nanchang, Jiangxi 330000, China
  • Research site16
    Linyi, Shandong 276002, China
  • Research site28
    Shanghai, Shanghai Municipality 200032, China
  • Research site23
    Xi’an, Shanxi 710000, China
  • Research site19
    Hangzhou, Zhejiang 310005, China
08

References and documents

Publications

  • Jiang L, Luo Y, Liang H, Feng X, Huang Y, Li Y, Wang Z, Xu T, Zou H, Li Z, Shen L, Chen Y, Wang W, Li J. The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRASG12C mutation. Hum Cell. 2026 Jul 1;39(7):95. doi: 10.1007/s13577-026-01405-0. PubMed 42384131 ↗
  • Li J, Wang Z, Huang J, Ba Y, Cao B, Luo S, Li W, Bai C, Song Z, Xiong J, Zhu L, An G, Zhang Y, Li Z, Li Y, Gu Y, Hu C, Li X, Huang C, Fu Q, Yin X, Liang X, Zhong D, Shi H, Li X, Li Z, Liu L, Wang F, Liang R, Xia G, Wang Z, Wang-Gillam A, Ding Y, Rao Z, Pan W, Lu S, Sun X, Shen L. Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials. Lancet Gastroenterol Hepatol. 2026 Feb;11(2):110-123. doi: 10.1016/S2468-1253(25)00267-5. Epub 2025 Dec 1. PubMed 41344351 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Apr 2025, 38 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2021
First posted
Jan 18, 2022
StartActual
Feb 17, 2022
Primary completionActual
Apr 30, 2025
CompletionEst.
Dec 2026
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05194995
Responsible party
Sponsor
First posted
Jan 18, 2022
Start date
Feb 17, 2022
Primary completion
Apr 30, 2025
Completion
Dec 2026 (estimated)
Last update
Mar 16, 2026

Study contacts

Shen Lin Master of medicine
principal investigator · Peking University Cancer Hospital & Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glecirasib

Start the discussion